BRCA1 mutation carriers also experienced significantly more frequent second primary malignancies compared to BRCA2 mutation carriers (breast cancer: 17.0% vs. 12.2%, p = 0.009; non-breast cancer: 4.3% vs. 1.9%, p = 0.02), while distant recurrences were less frequent (10.4% vs. 15.4%, p = 0.02) compared to the BRCA2 cohort [224]. This evidence concerns the gene BRCA2 and breast cancer.